top of page

Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego

  • Oct 27, 2024
  • 1 min read

Updated: Oct 28, 2024

Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR Stabilization, as well as reductions in Gd-IgA1, hematuria, and proteinuria.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page